634 related articles for article (PubMed ID: 11250889)
1. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
[TBL] [Abstract][Full Text] [Related]
2. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
[TBL] [Abstract][Full Text] [Related]
4. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K
FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system.
Kremer C; Breier G; Risau W; Plate KH
Cancer Res; 1997 Sep; 57(17):3852-9. PubMed ID: 9288799
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA; Paavonen K
Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
[TBL] [Abstract][Full Text] [Related]
9. [Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C].
Mandriota SJ; Pepper MS
J Soc Biol; 1999; 193(2):159-63. PubMed ID: 10451350
[TBL] [Abstract][Full Text] [Related]
10. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
Gilbert RE; Vranes D; Berka JL; Kelly DJ; Cox A; Wu LL; Stacker SA; Cooper ME
Lab Invest; 1998 Aug; 78(8):1017-27. PubMed ID: 9714188
[TBL] [Abstract][Full Text] [Related]
12. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis.
Mimura T; Amano S; Usui T; Kaji Y; Oshika T; Ishii Y
Exp Eye Res; 2001 Jan; 72(1):71-8. PubMed ID: 11133184
[TBL] [Abstract][Full Text] [Related]
13. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP
Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
15. VEGF receptor signaling and endothelial function.
Kliche S; Waltenberger J
IUBMB Life; 2001 Jul; 52(1-2):61-6. PubMed ID: 11795595
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
Karpanen T; Egeblad M; Karkkainen MJ; Kubo H; Ylä-Herttuala S; Jäättelä M; Alitalo K
Cancer Res; 2001 Mar; 61(5):1786-90. PubMed ID: 11280723
[TBL] [Abstract][Full Text] [Related]
17. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.
Clarijs R; Schalkwijk L; Ruiter DJ; de Waal RM
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1422-8. PubMed ID: 11381041
[TBL] [Abstract][Full Text] [Related]
18. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
Gerber HP; Malik AK; Solar GP; Sherman D; Liang XH; Meng G; Hong K; Marsters JC; Ferrara N
Nature; 2002 Jun; 417(6892):954-8. PubMed ID: 12087404
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins.
Gingras D; Lamy S; Béliveau R
Biochem J; 2000 Jun; 348 Pt 2(Pt 2):273-80. PubMed ID: 10816419
[TBL] [Abstract][Full Text] [Related]
20. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.
Larcher F; Murillas R; Bolontrade M; Conti CJ; Jorcano JL
Oncogene; 1998 Jul; 17(3):303-11. PubMed ID: 9690512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
